Strategic Partnerships AIM ImmunoTech is actively seeking senior co-development partners with capital and expertise to commercialize Ampligen and Alferon. This presents an opportunity to position your organization as a preferred collaborator for large-scale oncology and immunotherapy programs, especially in trials and potential market launches.

Clinical Momentum Recent conference presentations and Phase 2/3 trial activity, including pancreatic cancer and ovarian cancer data, indicate ongoing clinical momentum. This creates openings for CROs, data analytics partners, and translational research collaborators to support trial design, patient recruitment, and regulatory strategy.

Regional Focus Efforts toward Japanese Orphan Drug designation for Ampligen and expansion discussions in international markets suggest opportunities with regional partners, regulatory consultants, and market access specialists to navigate orphan drug processes and reimbursement pathways.

Manufacturing & Scale Current production at a 30,000-square-foot facility in New Brunswick, NJ signals potential needs for manufacturing optimization, tech transfer, capacity expansion, or contract manufacturing services to support deeper Phase 3 trials and potential commercial scale.

Strategic Finance Funding levels indicate room for strategic advisory, grant applications, or equity/debt financing support aligned with a growth/partnership narrative, as AIM seeks capital and expertise for later-stage commercialization and co-development deals.